Frontiers in Immunology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2262462, encodeId=a5ba2262462f5, content=审稿速度:1.0 偏重的研究方向：免疫调控 经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9679589603, createdName=ms4000000257993669, createdTime=Sun Apr 27 10:19:58 CST 2025, time=2025-04-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2261340, encodeId=f86b2261340ea, content=生信加验证1月投的，4月给大修，两个审稿人，第一个打分很低1121，一堆不满意，问题不多，第二个审稿人就一个问题，打分3323。修回后当天第一个审稿人同意发表，现在过了5天了在等第二个审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0afd5193394, createdName=Unparalled, createdTime=Mon Apr 21 01:36:48 CST 2025, time=2025-04-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183262, encodeId=699e21832625c, content=兄弟们，拒稿原因是Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是什么个情况啊。写的东西都快是全网唯一一个写这破主题的了，每个字都是自己码的，怎么可能会有诚信问题……有没有最近被拒的朋友也是这种情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5259154041, createdName=ms6000000464829773, createdTime=Mon Jan 22 19:55:02 CST 2024, time=2024-01-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2257234, encodeId=8567225e23452, content=审稿速度:1.0 偏重的研究方向：免疫 经验分享：我想问问😭返修回去以后多久会有决定啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434c9545381, createdName=ms9000001869013749, createdTime=Sat Mar 22 11:36:32 CST 2025, time=2025-03-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1224242, encodeId=3c5812242420d, content=各位大佬，我想问问当时选了一个topic的编辑，但是刚刚看这个topic已经截止了，我这篇文章在5月31已经上交修改稿了，已经过去三天了编辑最终还没有决定，会不会因为这个topic停止submit给我拒稿了呢？？两个审稿人的意见都还可以，还有就是当时上传留言的时候因为网页翻译问题，上传的回复全部变成了中文，审稿人（估计是中国人）finalized我才发现，又在编辑那边重新用英文留言一遍并道歉，这会对我产生很致命的负面吗？感谢你们的回答, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d068143459, createdName=ms6000001997807125, createdTime=Fri Jun 03 13:20:46 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164441, encodeId=0af821644417d, content=投完第二天让resubmit是什么意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f836152654, createdName=ms8000000979439920, createdTime=Mon Oct 23 19:26:42 CST 2023, time=2023-10-23, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2237608, encodeId=1620223e608db, content=审稿速度:24.0 | 投稿命中率:25.0 经验分享：现在好慢啊，投稿4个月没分配编辑。真服了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb896455475, createdName=ms4000001407861956, createdTime=Mon Nov 18 15:33:44 CST 2024, time=2024-11-18, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2251509, encodeId=d8e22251509fb, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肺癌 经验分享：21 Jan 2025 (12:22:40) Article accepted for publication. 10 Jan 2025 (12:23:49) Review of Reviewer 1 finalized. (11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript. (11:03:16) Corresponding Author Peng Xiuhua posted new comments. (10:27:56) Corresponding Author Peng Xiuhua posted new comments. 23 Dec 2024 (18:05:16) Review of Reviewer 2 finalized. (18:01:29) Reviewer 2 posted new comments. 20 Dec 2024 (09:46:36) Corresponding Author Peng Xiuhua posted new comments. 10 Dec 2024 (08:40:46) Interactive review forum activated. 24 Nov 2024 (13:36:44) Corresponding Author Peng Xiuhua submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47509306346, createdName=ms7000000739039843, createdTime=Tue Feb 11 20:39:18 CST 2025, time=2025-02-11, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251508, encodeId=fb5522515082b, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肺癌 经验分享：21 Jan 2025 (12:22:40) Article accepted for publication. 10 Jan 2025 (12:23:49) Review of Reviewer 1 finalized. (11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript. (11:03:16) Corresponding Author Peng Xiuhua posted new comments. (10:27:56) Corresponding Author Peng Xiuhua posted new comments. 23 Dec 2024 (18:05:16) Review of Reviewer 2 finalized. (18:01:29) Reviewer 2 posted new comments. 20 Dec 2024 (09:46:36) Corresponding Author Peng Xiuhua posted new comments. 10 Dec 2024 (08:40:46) Interactive review forum activated. 24 Nov 2024 (13:36:44) Corresponding Author Peng Xiuhua submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47509306346, createdName=ms7000000739039843, createdTime=Tue Feb 11 20:37:39 CST 2025, time=2025-02-11, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2246390, encodeId=2185224639036, content=我提交一篇文章已经1个月了，也不知道怎么查看现在的状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05072053931, createdName=huagangyan2018, createdTime=Fri Jan 03 16:21:34 CST 2025, time=2025-01-03, status=1, ipAttribution=广西)]

2025-04-27 ms4000000257993669 来自重庆

审稿速度:1.0
偏重的研究方向：免疫调控
经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息

3 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2262462, encodeId=a5ba2262462f5, content=审稿速度:1.0 偏重的研究方向：免疫调控 经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9679589603, createdName=ms4000000257993669, createdTime=Sun Apr 27 10:19:58 CST 2025, time=2025-04-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2261340, encodeId=f86b2261340ea, content=生信加验证1月投的，4月给大修，两个审稿人，第一个打分很低1121，一堆不满意，问题不多，第二个审稿人就一个问题，打分3323。修回后当天第一个审稿人同意发表，现在过了5天了在等第二个审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0afd5193394, createdName=Unparalled, createdTime=Mon Apr 21 01:36:48 CST 2025, time=2025-04-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183262, encodeId=699e21832625c, content=兄弟们，拒稿原因是Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是什么个情况啊。写的东西都快是全网唯一一个写这破主题的了，每个字都是自己码的，怎么可能会有诚信问题……有没有最近被拒的朋友也是这种情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5259154041, createdName=ms6000000464829773, createdTime=Mon Jan 22 19:55:02 CST 2024, time=2024-01-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2257234, encodeId=8567225e23452, content=审稿速度:1.0 偏重的研究方向：免疫 经验分享：我想问问😭返修回去以后多久会有决定啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434c9545381, createdName=ms9000001869013749, createdTime=Sat Mar 22 11:36:32 CST 2025, time=2025-03-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1224242, encodeId=3c5812242420d, content=各位大佬，我想问问当时选了一个topic的编辑，但是刚刚看这个topic已经截止了，我这篇文章在5月31已经上交修改稿了，已经过去三天了编辑最终还没有决定，会不会因为这个topic停止submit给我拒稿了呢？？两个审稿人的意见都还可以，还有就是当时上传留言的时候因为网页翻译问题，上传的回复全部变成了中文，审稿人（估计是中国人）finalized我才发现，又在编辑那边重新用英文留言一遍并道歉，这会对我产生很致命的负面吗？感谢你们的回答, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d068143459, createdName=ms6000001997807125, createdTime=Fri Jun 03 13:20:46 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164441, encodeId=0af821644417d, content=投完第二天让resubmit是什么意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f836152654, createdName=ms8000000979439920, createdTime=Mon Oct 23 19:26:42 CST 2023, time=2023-10-23, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2237608, encodeId=1620223e608db, content=审稿速度:24.0 | 投稿命中率:25.0 经验分享：现在好慢啊，投稿4个月没分配编辑。真服了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb896455475, createdName=ms4000001407861956, createdTime=Mon Nov 18 15:33:44 CST 2024, time=2024-11-18, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2251509, encodeId=d8e22251509fb, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肺癌 经验分享：21 Jan 2025 (12:22:40) Article accepted for publication. 10 Jan 2025 (12:23:49) Review of Reviewer 1 finalized. (11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript. (11:03:16) Corresponding Author Peng Xiuhua posted new comments. (10:27:56) Corresponding Author Peng Xiuhua posted new comments. 23 Dec 2024 (18:05:16) Review of Reviewer 2 finalized. (18:01:29) Reviewer 2 posted new comments. 20 Dec 2024 (09:46:36) Corresponding Author Peng Xiuhua posted new comments. 10 Dec 2024 (08:40:46) Interactive review forum activated. 24 Nov 2024 (13:36:44) Corresponding Author Peng Xiuhua submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47509306346, createdName=ms7000000739039843, createdTime=Tue Feb 11 20:39:18 CST 2025, time=2025-02-11, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251508, encodeId=fb5522515082b, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肺癌 经验分享：21 Jan 2025 (12:22:40) Article accepted for publication. 10 Jan 2025 (12:23:49) Review of Reviewer 1 finalized. (11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript. (11:03:16) Corresponding Author Peng Xiuhua posted new comments. (10:27:56) Corresponding Author Peng Xiuhua posted new comments. 23 Dec 2024 (18:05:16) Review of Reviewer 2 finalized. (18:01:29) Reviewer 2 posted new comments. 20 Dec 2024 (09:46:36) Corresponding Author Peng Xiuhua posted new comments. 10 Dec 2024 (08:40:46) Interactive review forum activated. 24 Nov 2024 (13:36:44) Corresponding Author Peng Xiuhua submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47509306346, createdName=ms7000000739039843, createdTime=Tue Feb 11 20:37:39 CST 2025, time=2025-02-11, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2246390, encodeId=2185224639036, content=我提交一篇文章已经1个月了，也不知道怎么查看现在的状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05072053931, createdName=huagangyan2018, createdTime=Fri Jan 03 16:21:34 CST 2025, time=2025-01-03, status=1, ipAttribution=广西)]

2025-04-21 Unparalled 来自浙江省

生信加验证1月投的，4月给大修，两个审稿人，第一个打分很低1121，一堆不满意，问题不多，第二个审稿人就一个问题，打分3323。修回后当天第一个审稿人同意发表，现在过了5天了在等第二个审稿人

5 0

[GetPortalCommentsPageByObjectIdResponse(id=2262462, encodeId=a5ba2262462f5, content=审稿速度:1.0 偏重的研究方向：免疫调控 经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9679589603, createdName=ms4000000257993669, createdTime=Sun Apr 27 10:19:58 CST 2025, time=2025-04-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2261340, encodeId=f86b2261340ea, content=生信加验证1月投的，4月给大修，两个审稿人，第一个打分很低1121，一堆不满意，问题不多，第二个审稿人就一个问题，打分3323。修回后当天第一个审稿人同意发表，现在过了5天了在等第二个审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0afd5193394, createdName=Unparalled, createdTime=Mon Apr 21 01:36:48 CST 2025, time=2025-04-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183262, encodeId=699e21832625c, content=兄弟们，拒稿原因是Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是什么个情况啊。写的东西都快是全网唯一一个写这破主题的了，每个字都是自己码的，怎么可能会有诚信问题……有没有最近被拒的朋友也是这种情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5259154041, createdName=ms6000000464829773, createdTime=Mon Jan 22 19:55:02 CST 2024, time=2024-01-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2257234, encodeId=8567225e23452, content=审稿速度:1.0 偏重的研究方向：免疫 经验分享：我想问问😭返修回去以后多久会有决定啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434c9545381, createdName=ms9000001869013749, createdTime=Sat Mar 22 11:36:32 CST 2025, time=2025-03-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1224242, encodeId=3c5812242420d, content=各位大佬，我想问问当时选了一个topic的编辑，但是刚刚看这个topic已经截止了，我这篇文章在5月31已经上交修改稿了，已经过去三天了编辑最终还没有决定，会不会因为这个topic停止submit给我拒稿了呢？？两个审稿人的意见都还可以，还有就是当时上传留言的时候因为网页翻译问题，上传的回复全部变成了中文，审稿人（估计是中国人）finalized我才发现，又在编辑那边重新用英文留言一遍并道歉，这会对我产生很致命的负面吗？感谢你们的回答, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d068143459, createdName=ms6000001997807125, createdTime=Fri Jun 03 13:20:46 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164441, encodeId=0af821644417d, content=投完第二天让resubmit是什么意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f836152654, createdName=ms8000000979439920, createdTime=Mon Oct 23 19:26:42 CST 2023, time=2023-10-23, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2237608, encodeId=1620223e608db, content=审稿速度:24.0 | 投稿命中率:25.0 经验分享：现在好慢啊，投稿4个月没分配编辑。真服了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb896455475, createdName=ms4000001407861956, createdTime=Mon Nov 18 15:33:44 CST 2024, time=2024-11-18, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2251509, encodeId=d8e22251509fb, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肺癌 经验分享：21 Jan 2025 (12:22:40) Article accepted for publication. 10 Jan 2025 (12:23:49) Review of Reviewer 1 finalized. (11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript. (11:03:16) Corresponding Author Peng Xiuhua posted new comments. (10:27:56) Corresponding Author Peng Xiuhua posted new comments. 23 Dec 2024 (18:05:16) Review of Reviewer 2 finalized. (18:01:29) Reviewer 2 posted new comments. 20 Dec 2024 (09:46:36) Corresponding Author Peng Xiuhua posted new comments. 10 Dec 2024 (08:40:46) Interactive review forum activated. 24 Nov 2024 (13:36:44) Corresponding Author Peng Xiuhua submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47509306346, createdName=ms7000000739039843, createdTime=Tue Feb 11 20:39:18 CST 2025, time=2025-02-11, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251508, encodeId=fb5522515082b, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肺癌 经验分享：21 Jan 2025 (12:22:40) Article accepted for publication. 10 Jan 2025 (12:23:49) Review of Reviewer 1 finalized. (11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript. (11:03:16) Corresponding Author Peng Xiuhua posted new comments. (10:27:56) Corresponding Author Peng Xiuhua posted new comments. 23 Dec 2024 (18:05:16) Review of Reviewer 2 finalized. (18:01:29) Reviewer 2 posted new comments. 20 Dec 2024 (09:46:36) Corresponding Author Peng Xiuhua posted new comments. 10 Dec 2024 (08:40:46) Interactive review forum activated. 24 Nov 2024 (13:36:44) Corresponding Author Peng Xiuhua submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47509306346, createdName=ms7000000739039843, createdTime=Tue Feb 11 20:37:39 CST 2025, time=2025-02-11, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2246390, encodeId=2185224639036, content=我提交一篇文章已经1个月了，也不知道怎么查看现在的状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05072053931, createdName=huagangyan2018, createdTime=Fri Jan 03 16:21:34 CST 2025, time=2025-01-03, status=1, ipAttribution=广西)]

2024-01-22 ms6000000464829773 来自北京

兄弟们，拒稿原因是Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是什么个情况啊。写的东西都快是全网唯一一个写这破主题的了，每个字都是自己码的，怎么可能会有诚信问题……有没有最近被拒的朋友也是这种情况的？

202 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2262462, encodeId=a5ba2262462f5, content=审稿速度:1.0 偏重的研究方向：免疫调控 经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9679589603, createdName=ms4000000257993669, createdTime=Sun Apr 27 10:19:58 CST 2025, time=2025-04-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2261340, encodeId=f86b2261340ea, content=生信加验证1月投的，4月给大修，两个审稿人，第一个打分很低1121，一堆不满意，问题不多，第二个审稿人就一个问题，打分3323。修回后当天第一个审稿人同意发表，现在过了5天了在等第二个审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0afd5193394, createdName=Unparalled, createdTime=Mon Apr 21 01:36:48 CST 2025, time=2025-04-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183262, encodeId=699e21832625c, content=兄弟们，拒稿原因是Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是什么个情况啊。写的东西都快是全网唯一一个写这破主题的了，每个字都是自己码的，怎么可能会有诚信问题……有没有最近被拒的朋友也是这种情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5259154041, createdName=ms6000000464829773, createdTime=Mon Jan 22 19:55:02 CST 2024, time=2024-01-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2257234, encodeId=8567225e23452, content=审稿速度:1.0 偏重的研究方向：免疫 经验分享：我想问问😭返修回去以后多久会有决定啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434c9545381, createdName=ms9000001869013749, createdTime=Sat Mar 22 11:36:32 CST 2025, time=2025-03-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1224242, encodeId=3c5812242420d, content=各位大佬，我想问问当时选了一个topic的编辑，但是刚刚看这个topic已经截止了，我这篇文章在5月31已经上交修改稿了，已经过去三天了编辑最终还没有决定，会不会因为这个topic停止submit给我拒稿了呢？？两个审稿人的意见都还可以，还有就是当时上传留言的时候因为网页翻译问题，上传的回复全部变成了中文，审稿人（估计是中国人）finalized我才发现，又在编辑那边重新用英文留言一遍并道歉，这会对我产生很致命的负面吗？感谢你们的回答, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d068143459, createdName=ms6000001997807125, createdTime=Fri Jun 03 13:20:46 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164441, encodeId=0af821644417d, content=投完第二天让resubmit是什么意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f836152654, createdName=ms8000000979439920, createdTime=Mon Oct 23 19:26:42 CST 2023, time=2023-10-23, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2237608, encodeId=1620223e608db, content=审稿速度:24.0 | 投稿命中率:25.0 经验分享：现在好慢啊，投稿4个月没分配编辑。真服了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb896455475, createdName=ms4000001407861956, createdTime=Mon Nov 18 15:33:44 CST 2024, time=2024-11-18, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2251509, encodeId=d8e22251509fb, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肺癌 经验分享：21 Jan 2025 (12:22:40) Article accepted for publication. 10 Jan 2025 (12:23:49) Review of Reviewer 1 finalized. (11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript. (11:03:16) Corresponding Author Peng Xiuhua posted new comments. (10:27:56) Corresponding Author Peng Xiuhua posted new comments. 23 Dec 2024 (18:05:16) Review of Reviewer 2 finalized. (18:01:29) Reviewer 2 posted new comments. 20 Dec 2024 (09:46:36) Corresponding Author Peng Xiuhua posted new comments. 10 Dec 2024 (08:40:46) Interactive review forum activated. 24 Nov 2024 (13:36:44) Corresponding Author Peng Xiuhua submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47509306346, createdName=ms7000000739039843, createdTime=Tue Feb 11 20:39:18 CST 2025, time=2025-02-11, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251508, encodeId=fb5522515082b, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肺癌 经验分享：21 Jan 2025 (12:22:40) Article accepted for publication. 10 Jan 2025 (12:23:49) Review of Reviewer 1 finalized. (11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript. (11:03:16) Corresponding Author Peng Xiuhua posted new comments. (10:27:56) Corresponding Author Peng Xiuhua posted new comments. 23 Dec 2024 (18:05:16) Review of Reviewer 2 finalized. (18:01:29) Reviewer 2 posted new comments. 20 Dec 2024 (09:46:36) Corresponding Author Peng Xiuhua posted new comments. 10 Dec 2024 (08:40:46) Interactive review forum activated. 24 Nov 2024 (13:36:44) Corresponding Author Peng Xiuhua submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47509306346, createdName=ms7000000739039843, createdTime=Tue Feb 11 20:37:39 CST 2025, time=2025-02-11, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2246390, encodeId=2185224639036, content=我提交一篇文章已经1个月了，也不知道怎么查看现在的状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05072053931, createdName=huagangyan2018, createdTime=Fri Jan 03 16:21:34 CST 2025, time=2025-01-03, status=1, ipAttribution=广西)]

2025-03-22 ms9000001869013749 来自江苏省

审稿速度:1.0
偏重的研究方向：免疫
经验分享：我想问问😭返修回去以后多久会有决定啊

19 0

[GetPortalCommentsPageByObjectIdResponse(id=2262462, encodeId=a5ba2262462f5, content=审稿速度:1.0 偏重的研究方向：免疫调控 经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9679589603, createdName=ms4000000257993669, createdTime=Sun Apr 27 10:19:58 CST 2025, time=2025-04-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2261340, encodeId=f86b2261340ea, content=生信加验证1月投的，4月给大修，两个审稿人，第一个打分很低1121，一堆不满意，问题不多，第二个审稿人就一个问题，打分3323。修回后当天第一个审稿人同意发表，现在过了5天了在等第二个审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0afd5193394, createdName=Unparalled, createdTime=Mon Apr 21 01:36:48 CST 2025, time=2025-04-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183262, encodeId=699e21832625c, content=兄弟们，拒稿原因是Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是什么个情况啊。写的东西都快是全网唯一一个写这破主题的了，每个字都是自己码的，怎么可能会有诚信问题……有没有最近被拒的朋友也是这种情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5259154041, createdName=ms6000000464829773, createdTime=Mon Jan 22 19:55:02 CST 2024, time=2024-01-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2257234, encodeId=8567225e23452, content=审稿速度:1.0 偏重的研究方向：免疫 经验分享：我想问问😭返修回去以后多久会有决定啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434c9545381, createdName=ms9000001869013749, createdTime=Sat Mar 22 11:36:32 CST 2025, time=2025-03-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1224242, encodeId=3c5812242420d, content=各位大佬，我想问问当时选了一个topic的编辑，但是刚刚看这个topic已经截止了，我这篇文章在5月31已经上交修改稿了，已经过去三天了编辑最终还没有决定，会不会因为这个topic停止submit给我拒稿了呢？？两个审稿人的意见都还可以，还有就是当时上传留言的时候因为网页翻译问题，上传的回复全部变成了中文，审稿人（估计是中国人）finalized我才发现，又在编辑那边重新用英文留言一遍并道歉，这会对我产生很致命的负面吗？感谢你们的回答, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d068143459, createdName=ms6000001997807125, createdTime=Fri Jun 03 13:20:46 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164441, encodeId=0af821644417d, content=投完第二天让resubmit是什么意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f836152654, createdName=ms8000000979439920, createdTime=Mon Oct 23 19:26:42 CST 2023, time=2023-10-23, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2237608, encodeId=1620223e608db, content=审稿速度:24.0 | 投稿命中率:25.0 经验分享：现在好慢啊，投稿4个月没分配编辑。真服了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb896455475, createdName=ms4000001407861956, createdTime=Mon Nov 18 15:33:44 CST 2024, time=2024-11-18, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2251509, encodeId=d8e22251509fb, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肺癌 经验分享：21 Jan 2025 (12:22:40) Article accepted for publication. 10 Jan 2025 (12:23:49) Review of Reviewer 1 finalized. (11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript. (11:03:16) Corresponding Author Peng Xiuhua posted new comments. (10:27:56) Corresponding Author Peng Xiuhua posted new comments. 23 Dec 2024 (18:05:16) Review of Reviewer 2 finalized. (18:01:29) Reviewer 2 posted new comments. 20 Dec 2024 (09:46:36) Corresponding Author Peng Xiuhua posted new comments. 10 Dec 2024 (08:40:46) Interactive review forum activated. 24 Nov 2024 (13:36:44) Corresponding Author Peng Xiuhua submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47509306346, createdName=ms7000000739039843, createdTime=Tue Feb 11 20:39:18 CST 2025, time=2025-02-11, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251508, encodeId=fb5522515082b, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肺癌 经验分享：21 Jan 2025 (12:22:40) Article accepted for publication. 10 Jan 2025 (12:23:49) Review of Reviewer 1 finalized. (11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript. (11:03:16) Corresponding Author Peng Xiuhua posted new comments. (10:27:56) Corresponding Author Peng Xiuhua posted new comments. 23 Dec 2024 (18:05:16) Review of Reviewer 2 finalized. (18:01:29) Reviewer 2 posted new comments. 20 Dec 2024 (09:46:36) Corresponding Author Peng Xiuhua posted new comments. 10 Dec 2024 (08:40:46) Interactive review forum activated. 24 Nov 2024 (13:36:44) Corresponding Author Peng Xiuhua submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47509306346, createdName=ms7000000739039843, createdTime=Tue Feb 11 20:37:39 CST 2025, time=2025-02-11, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2246390, encodeId=2185224639036, content=我提交一篇文章已经1个月了，也不知道怎么查看现在的状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05072053931, createdName=huagangyan2018, createdTime=Fri Jan 03 16:21:34 CST 2025, time=2025-01-03, status=1, ipAttribution=广西)]

2022-06-03 ms6000001997807125

各位大佬，我想问问当时选了一个topic的编辑，但是刚刚看这个topic已经截止了，我这篇文章在5月31已经上交修改稿了，已经过去三天了编辑最终还没有决定，会不会因为这个topic停止submit给我拒稿了呢？？两个审稿人的意见都还可以，还有就是当时上传留言的时候因为网页翻译问题，上传的回复全部变成了中文，审稿人（估计是中国人）finalized我才发现，又在编辑那边重新用英文留言一遍并道歉，这会对我产生很致命的负面吗？感谢你们的回答

83 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2262462, encodeId=a5ba2262462f5, content=审稿速度:1.0 偏重的研究方向：免疫调控 经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9679589603, createdName=ms4000000257993669, createdTime=Sun Apr 27 10:19:58 CST 2025, time=2025-04-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2261340, encodeId=f86b2261340ea, content=生信加验证1月投的，4月给大修，两个审稿人，第一个打分很低1121，一堆不满意，问题不多，第二个审稿人就一个问题，打分3323。修回后当天第一个审稿人同意发表，现在过了5天了在等第二个审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0afd5193394, createdName=Unparalled, createdTime=Mon Apr 21 01:36:48 CST 2025, time=2025-04-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183262, encodeId=699e21832625c, content=兄弟们，拒稿原因是Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是什么个情况啊。写的东西都快是全网唯一一个写这破主题的了，每个字都是自己码的，怎么可能会有诚信问题……有没有最近被拒的朋友也是这种情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5259154041, createdName=ms6000000464829773, createdTime=Mon Jan 22 19:55:02 CST 2024, time=2024-01-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2257234, encodeId=8567225e23452, content=审稿速度:1.0 偏重的研究方向：免疫 经验分享：我想问问😭返修回去以后多久会有决定啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434c9545381, createdName=ms9000001869013749, createdTime=Sat Mar 22 11:36:32 CST 2025, time=2025-03-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1224242, encodeId=3c5812242420d, content=各位大佬，我想问问当时选了一个topic的编辑，但是刚刚看这个topic已经截止了，我这篇文章在5月31已经上交修改稿了，已经过去三天了编辑最终还没有决定，会不会因为这个topic停止submit给我拒稿了呢？？两个审稿人的意见都还可以，还有就是当时上传留言的时候因为网页翻译问题，上传的回复全部变成了中文，审稿人（估计是中国人）finalized我才发现，又在编辑那边重新用英文留言一遍并道歉，这会对我产生很致命的负面吗？感谢你们的回答, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d068143459, createdName=ms6000001997807125, createdTime=Fri Jun 03 13:20:46 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164441, encodeId=0af821644417d, content=投完第二天让resubmit是什么意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f836152654, createdName=ms8000000979439920, createdTime=Mon Oct 23 19:26:42 CST 2023, time=2023-10-23, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2237608, encodeId=1620223e608db, content=审稿速度:24.0 | 投稿命中率:25.0 经验分享：现在好慢啊，投稿4个月没分配编辑。真服了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb896455475, createdName=ms4000001407861956, createdTime=Mon Nov 18 15:33:44 CST 2024, time=2024-11-18, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2251509, encodeId=d8e22251509fb, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肺癌 经验分享：21 Jan 2025 (12:22:40) Article accepted for publication. 10 Jan 2025 (12:23:49) Review of Reviewer 1 finalized. (11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript. (11:03:16) Corresponding Author Peng Xiuhua posted new comments. (10:27:56) Corresponding Author Peng Xiuhua posted new comments. 23 Dec 2024 (18:05:16) Review of Reviewer 2 finalized. (18:01:29) Reviewer 2 posted new comments. 20 Dec 2024 (09:46:36) Corresponding Author Peng Xiuhua posted new comments. 10 Dec 2024 (08:40:46) Interactive review forum activated. 24 Nov 2024 (13:36:44) Corresponding Author Peng Xiuhua submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47509306346, createdName=ms7000000739039843, createdTime=Tue Feb 11 20:39:18 CST 2025, time=2025-02-11, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251508, encodeId=fb5522515082b, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肺癌 经验分享：21 Jan 2025 (12:22:40) Article accepted for publication. 10 Jan 2025 (12:23:49) Review of Reviewer 1 finalized. (11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript. (11:03:16) Corresponding Author Peng Xiuhua posted new comments. (10:27:56) Corresponding Author Peng Xiuhua posted new comments. 23 Dec 2024 (18:05:16) Review of Reviewer 2 finalized. (18:01:29) Reviewer 2 posted new comments. 20 Dec 2024 (09:46:36) Corresponding Author Peng Xiuhua posted new comments. 10 Dec 2024 (08:40:46) Interactive review forum activated. 24 Nov 2024 (13:36:44) Corresponding Author Peng Xiuhua submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47509306346, createdName=ms7000000739039843, createdTime=Tue Feb 11 20:37:39 CST 2025, time=2025-02-11, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2246390, encodeId=2185224639036, content=我提交一篇文章已经1个月了，也不知道怎么查看现在的状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05072053931, createdName=huagangyan2018, createdTime=Fri Jan 03 16:21:34 CST 2025, time=2025-01-03, status=1, ipAttribution=广西)]

2023-10-23 ms8000000979439920 来自吉林省

投完第二天让resubmit是什么意思

61 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2262462, encodeId=a5ba2262462f5, content=审稿速度:1.0 偏重的研究方向：免疫调控 经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9679589603, createdName=ms4000000257993669, createdTime=Sun Apr 27 10:19:58 CST 2025, time=2025-04-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2261340, encodeId=f86b2261340ea, content=生信加验证1月投的，4月给大修，两个审稿人，第一个打分很低1121，一堆不满意，问题不多，第二个审稿人就一个问题，打分3323。修回后当天第一个审稿人同意发表，现在过了5天了在等第二个审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0afd5193394, createdName=Unparalled, createdTime=Mon Apr 21 01:36:48 CST 2025, time=2025-04-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183262, encodeId=699e21832625c, content=兄弟们，拒稿原因是Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是什么个情况啊。写的东西都快是全网唯一一个写这破主题的了，每个字都是自己码的，怎么可能会有诚信问题……有没有最近被拒的朋友也是这种情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5259154041, createdName=ms6000000464829773, createdTime=Mon Jan 22 19:55:02 CST 2024, time=2024-01-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2257234, encodeId=8567225e23452, content=审稿速度:1.0 偏重的研究方向：免疫 经验分享：我想问问😭返修回去以后多久会有决定啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434c9545381, createdName=ms9000001869013749, createdTime=Sat Mar 22 11:36:32 CST 2025, time=2025-03-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1224242, encodeId=3c5812242420d, content=各位大佬，我想问问当时选了一个topic的编辑，但是刚刚看这个topic已经截止了，我这篇文章在5月31已经上交修改稿了，已经过去三天了编辑最终还没有决定，会不会因为这个topic停止submit给我拒稿了呢？？两个审稿人的意见都还可以，还有就是当时上传留言的时候因为网页翻译问题，上传的回复全部变成了中文，审稿人（估计是中国人）finalized我才发现，又在编辑那边重新用英文留言一遍并道歉，这会对我产生很致命的负面吗？感谢你们的回答, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d068143459, createdName=ms6000001997807125, createdTime=Fri Jun 03 13:20:46 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164441, encodeId=0af821644417d, content=投完第二天让resubmit是什么意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f836152654, createdName=ms8000000979439920, createdTime=Mon Oct 23 19:26:42 CST 2023, time=2023-10-23, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2237608, encodeId=1620223e608db, content=审稿速度:24.0 | 投稿命中率:25.0 经验分享：现在好慢啊，投稿4个月没分配编辑。真服了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb896455475, createdName=ms4000001407861956, createdTime=Mon Nov 18 15:33:44 CST 2024, time=2024-11-18, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2251509, encodeId=d8e22251509fb, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肺癌 经验分享：21 Jan 2025 (12:22:40) Article accepted for publication. 10 Jan 2025 (12:23:49) Review of Reviewer 1 finalized. (11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript. (11:03:16) Corresponding Author Peng Xiuhua posted new comments. (10:27:56) Corresponding Author Peng Xiuhua posted new comments. 23 Dec 2024 (18:05:16) Review of Reviewer 2 finalized. (18:01:29) Reviewer 2 posted new comments. 20 Dec 2024 (09:46:36) Corresponding Author Peng Xiuhua posted new comments. 10 Dec 2024 (08:40:46) Interactive review forum activated. 24 Nov 2024 (13:36:44) Corresponding Author Peng Xiuhua submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47509306346, createdName=ms7000000739039843, createdTime=Tue Feb 11 20:39:18 CST 2025, time=2025-02-11, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251508, encodeId=fb5522515082b, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肺癌 经验分享：21 Jan 2025 (12:22:40) Article accepted for publication. 10 Jan 2025 (12:23:49) Review of Reviewer 1 finalized. (11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript. (11:03:16) Corresponding Author Peng Xiuhua posted new comments. (10:27:56) Corresponding Author Peng Xiuhua posted new comments. 23 Dec 2024 (18:05:16) Review of Reviewer 2 finalized. (18:01:29) Reviewer 2 posted new comments. 20 Dec 2024 (09:46:36) Corresponding Author Peng Xiuhua posted new comments. 10 Dec 2024 (08:40:46) Interactive review forum activated. 24 Nov 2024 (13:36:44) Corresponding Author Peng Xiuhua submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47509306346, createdName=ms7000000739039843, createdTime=Tue Feb 11 20:37:39 CST 2025, time=2025-02-11, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2246390, encodeId=2185224639036, content=我提交一篇文章已经1个月了，也不知道怎么查看现在的状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05072053931, createdName=huagangyan2018, createdTime=Fri Jan 03 16:21:34 CST 2025, time=2025-01-03, status=1, ipAttribution=广西)]

2024-11-18 ms4000001407861956 来自河南省

审稿速度:24.0 | 投稿命中率:25.0
经验分享：现在好慢啊，投稿4个月没分配编辑。真服了。

59 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2262462, encodeId=a5ba2262462f5, content=审稿速度:1.0 偏重的研究方向：免疫调控 经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9679589603, createdName=ms4000000257993669, createdTime=Sun Apr 27 10:19:58 CST 2025, time=2025-04-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2261340, encodeId=f86b2261340ea, content=生信加验证1月投的，4月给大修，两个审稿人，第一个打分很低1121，一堆不满意，问题不多，第二个审稿人就一个问题，打分3323。修回后当天第一个审稿人同意发表，现在过了5天了在等第二个审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0afd5193394, createdName=Unparalled, createdTime=Mon Apr 21 01:36:48 CST 2025, time=2025-04-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183262, encodeId=699e21832625c, content=兄弟们，拒稿原因是Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是什么个情况啊。写的东西都快是全网唯一一个写这破主题的了，每个字都是自己码的，怎么可能会有诚信问题……有没有最近被拒的朋友也是这种情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5259154041, createdName=ms6000000464829773, createdTime=Mon Jan 22 19:55:02 CST 2024, time=2024-01-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2257234, encodeId=8567225e23452, content=审稿速度:1.0 偏重的研究方向：免疫 经验分享：我想问问😭返修回去以后多久会有决定啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434c9545381, createdName=ms9000001869013749, createdTime=Sat Mar 22 11:36:32 CST 2025, time=2025-03-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1224242, encodeId=3c5812242420d, content=各位大佬，我想问问当时选了一个topic的编辑，但是刚刚看这个topic已经截止了，我这篇文章在5月31已经上交修改稿了，已经过去三天了编辑最终还没有决定，会不会因为这个topic停止submit给我拒稿了呢？？两个审稿人的意见都还可以，还有就是当时上传留言的时候因为网页翻译问题，上传的回复全部变成了中文，审稿人（估计是中国人）finalized我才发现，又在编辑那边重新用英文留言一遍并道歉，这会对我产生很致命的负面吗？感谢你们的回答, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d068143459, createdName=ms6000001997807125, createdTime=Fri Jun 03 13:20:46 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164441, encodeId=0af821644417d, content=投完第二天让resubmit是什么意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f836152654, createdName=ms8000000979439920, createdTime=Mon Oct 23 19:26:42 CST 2023, time=2023-10-23, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2237608, encodeId=1620223e608db, content=审稿速度:24.0 | 投稿命中率:25.0 经验分享：现在好慢啊，投稿4个月没分配编辑。真服了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb896455475, createdName=ms4000001407861956, createdTime=Mon Nov 18 15:33:44 CST 2024, time=2024-11-18, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2251509, encodeId=d8e22251509fb, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肺癌 经验分享：21 Jan 2025 (12:22:40) Article accepted for publication. 10 Jan 2025 (12:23:49) Review of Reviewer 1 finalized. (11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript. (11:03:16) Corresponding Author Peng Xiuhua posted new comments. (10:27:56) Corresponding Author Peng Xiuhua posted new comments. 23 Dec 2024 (18:05:16) Review of Reviewer 2 finalized. (18:01:29) Reviewer 2 posted new comments. 20 Dec 2024 (09:46:36) Corresponding Author Peng Xiuhua posted new comments. 10 Dec 2024 (08:40:46) Interactive review forum activated. 24 Nov 2024 (13:36:44) Corresponding Author Peng Xiuhua submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47509306346, createdName=ms7000000739039843, createdTime=Tue Feb 11 20:39:18 CST 2025, time=2025-02-11, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251508, encodeId=fb5522515082b, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肺癌 经验分享：21 Jan 2025 (12:22:40) Article accepted for publication. 10 Jan 2025 (12:23:49) Review of Reviewer 1 finalized. (11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript. (11:03:16) Corresponding Author Peng Xiuhua posted new comments. (10:27:56) Corresponding Author Peng Xiuhua posted new comments. 23 Dec 2024 (18:05:16) Review of Reviewer 2 finalized. (18:01:29) Reviewer 2 posted new comments. 20 Dec 2024 (09:46:36) Corresponding Author Peng Xiuhua posted new comments. 10 Dec 2024 (08:40:46) Interactive review forum activated. 24 Nov 2024 (13:36:44) Corresponding Author Peng Xiuhua submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47509306346, createdName=ms7000000739039843, createdTime=Tue Feb 11 20:37:39 CST 2025, time=2025-02-11, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2246390, encodeId=2185224639036, content=我提交一篇文章已经1个月了，也不知道怎么查看现在的状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05072053931, createdName=huagangyan2018, createdTime=Fri Jan 03 16:21:34 CST 2025, time=2025-01-03, status=1, ipAttribution=广西)]

2025-02-11 ms7000000739039843 来自上海

审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向：肺癌
经验分享：21 Jan 2025
(12:22:40) Article accepted for publication.
10 Jan 2025
(12:23:49) Review of Reviewer 1 finalized.
(11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript.
(11:03:16) Corresponding Author Peng Xiuhua posted new comments.
(10:27:56) Corresponding Author Peng Xiuhua posted new comments.
23 Dec 2024
(18:05:16) Review of Reviewer 2 finalized.
(18:01:29) Reviewer 2 posted new comments.
20 Dec 2024
(09:46:36) Corresponding Author Peng Xiuhua posted new comments.
10 Dec 2024
(08:40:46) Interactive review forum activated.
24 Nov 2024
(13:36:44) Corresponding Author Peng Xiuhua submitted manuscript.

23 0

[GetPortalCommentsPageByObjectIdResponse(id=2262462, encodeId=a5ba2262462f5, content=审稿速度:1.0 偏重的研究方向：免疫调控 经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9679589603, createdName=ms4000000257993669, createdTime=Sun Apr 27 10:19:58 CST 2025, time=2025-04-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2261340, encodeId=f86b2261340ea, content=生信加验证1月投的，4月给大修，两个审稿人，第一个打分很低1121，一堆不满意，问题不多，第二个审稿人就一个问题，打分3323。修回后当天第一个审稿人同意发表，现在过了5天了在等第二个审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0afd5193394, createdName=Unparalled, createdTime=Mon Apr 21 01:36:48 CST 2025, time=2025-04-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183262, encodeId=699e21832625c, content=兄弟们，拒稿原因是Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是什么个情况啊。写的东西都快是全网唯一一个写这破主题的了，每个字都是自己码的，怎么可能会有诚信问题……有没有最近被拒的朋友也是这种情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5259154041, createdName=ms6000000464829773, createdTime=Mon Jan 22 19:55:02 CST 2024, time=2024-01-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2257234, encodeId=8567225e23452, content=审稿速度:1.0 偏重的研究方向：免疫 经验分享：我想问问😭返修回去以后多久会有决定啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434c9545381, createdName=ms9000001869013749, createdTime=Sat Mar 22 11:36:32 CST 2025, time=2025-03-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1224242, encodeId=3c5812242420d, content=各位大佬，我想问问当时选了一个topic的编辑，但是刚刚看这个topic已经截止了，我这篇文章在5月31已经上交修改稿了，已经过去三天了编辑最终还没有决定，会不会因为这个topic停止submit给我拒稿了呢？？两个审稿人的意见都还可以，还有就是当时上传留言的时候因为网页翻译问题，上传的回复全部变成了中文，审稿人（估计是中国人）finalized我才发现，又在编辑那边重新用英文留言一遍并道歉，这会对我产生很致命的负面吗？感谢你们的回答, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d068143459, createdName=ms6000001997807125, createdTime=Fri Jun 03 13:20:46 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164441, encodeId=0af821644417d, content=投完第二天让resubmit是什么意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f836152654, createdName=ms8000000979439920, createdTime=Mon Oct 23 19:26:42 CST 2023, time=2023-10-23, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2237608, encodeId=1620223e608db, content=审稿速度:24.0 | 投稿命中率:25.0 经验分享：现在好慢啊，投稿4个月没分配编辑。真服了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb896455475, createdName=ms4000001407861956, createdTime=Mon Nov 18 15:33:44 CST 2024, time=2024-11-18, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2251509, encodeId=d8e22251509fb, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肺癌 经验分享：21 Jan 2025 (12:22:40) Article accepted for publication. 10 Jan 2025 (12:23:49) Review of Reviewer 1 finalized. (11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript. (11:03:16) Corresponding Author Peng Xiuhua posted new comments. (10:27:56) Corresponding Author Peng Xiuhua posted new comments. 23 Dec 2024 (18:05:16) Review of Reviewer 2 finalized. (18:01:29) Reviewer 2 posted new comments. 20 Dec 2024 (09:46:36) Corresponding Author Peng Xiuhua posted new comments. 10 Dec 2024 (08:40:46) Interactive review forum activated. 24 Nov 2024 (13:36:44) Corresponding Author Peng Xiuhua submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47509306346, createdName=ms7000000739039843, createdTime=Tue Feb 11 20:39:18 CST 2025, time=2025-02-11, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251508, encodeId=fb5522515082b, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肺癌 经验分享：21 Jan 2025 (12:22:40) Article accepted for publication. 10 Jan 2025 (12:23:49) Review of Reviewer 1 finalized. (11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript. (11:03:16) Corresponding Author Peng Xiuhua posted new comments. (10:27:56) Corresponding Author Peng Xiuhua posted new comments. 23 Dec 2024 (18:05:16) Review of Reviewer 2 finalized. (18:01:29) Reviewer 2 posted new comments. 20 Dec 2024 (09:46:36) Corresponding Author Peng Xiuhua posted new comments. 10 Dec 2024 (08:40:46) Interactive review forum activated. 24 Nov 2024 (13:36:44) Corresponding Author Peng Xiuhua submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47509306346, createdName=ms7000000739039843, createdTime=Tue Feb 11 20:37:39 CST 2025, time=2025-02-11, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2246390, encodeId=2185224639036, content=我提交一篇文章已经1个月了，也不知道怎么查看现在的状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05072053931, createdName=huagangyan2018, createdTime=Fri Jan 03 16:21:34 CST 2025, time=2025-01-03, status=1, ipAttribution=广西)]

2025-02-11 ms7000000739039843 来自上海

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：肺癌
经验分享：21 Jan 2025
(12:22:40) Article accepted for publication.
10 Jan 2025
(12:23:49) Review of Reviewer 1 finalized.
(11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript.
(11:03:16) Corresponding Author Peng Xiuhua posted new comments.
(10:27:56) Corresponding Author Peng Xiuhua posted new comments.
23 Dec 2024
(18:05:16) Review of Reviewer 2 finalized.
(18:01:29) Reviewer 2 posted new comments.
20 Dec 2024
(09:46:36) Corresponding Author Peng Xiuhua posted new comments.
10 Dec 2024
(08:40:46) Interactive review forum activated.
24 Nov 2024
(13:36:44) Corresponding Author Peng Xiuhua submitted manuscript.

22 0

[GetPortalCommentsPageByObjectIdResponse(id=2262462, encodeId=a5ba2262462f5, content=审稿速度:1.0 偏重的研究方向：免疫调控 经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9679589603, createdName=ms4000000257993669, createdTime=Sun Apr 27 10:19:58 CST 2025, time=2025-04-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2261340, encodeId=f86b2261340ea, content=生信加验证1月投的，4月给大修，两个审稿人，第一个打分很低1121，一堆不满意，问题不多，第二个审稿人就一个问题，打分3323。修回后当天第一个审稿人同意发表，现在过了5天了在等第二个审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0afd5193394, createdName=Unparalled, createdTime=Mon Apr 21 01:36:48 CST 2025, time=2025-04-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183262, encodeId=699e21832625c, content=兄弟们，拒稿原因是Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是什么个情况啊。写的东西都快是全网唯一一个写这破主题的了，每个字都是自己码的，怎么可能会有诚信问题……有没有最近被拒的朋友也是这种情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5259154041, createdName=ms6000000464829773, createdTime=Mon Jan 22 19:55:02 CST 2024, time=2024-01-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2257234, encodeId=8567225e23452, content=审稿速度:1.0 偏重的研究方向：免疫 经验分享：我想问问😭返修回去以后多久会有决定啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434c9545381, createdName=ms9000001869013749, createdTime=Sat Mar 22 11:36:32 CST 2025, time=2025-03-22, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1224242, encodeId=3c5812242420d, content=各位大佬，我想问问当时选了一个topic的编辑，但是刚刚看这个topic已经截止了，我这篇文章在5月31已经上交修改稿了，已经过去三天了编辑最终还没有决定，会不会因为这个topic停止submit给我拒稿了呢？？两个审稿人的意见都还可以，还有就是当时上传留言的时候因为网页翻译问题，上传的回复全部变成了中文，审稿人（估计是中国人）finalized我才发现，又在编辑那边重新用英文留言一遍并道歉，这会对我产生很致命的负面吗？感谢你们的回答, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d068143459, createdName=ms6000001997807125, createdTime=Fri Jun 03 13:20:46 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164441, encodeId=0af821644417d, content=投完第二天让resubmit是什么意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f836152654, createdName=ms8000000979439920, createdTime=Mon Oct 23 19:26:42 CST 2023, time=2023-10-23, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2237608, encodeId=1620223e608db, content=审稿速度:24.0 | 投稿命中率:25.0 经验分享：现在好慢啊，投稿4个月没分配编辑。真服了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb896455475, createdName=ms4000001407861956, createdTime=Mon Nov 18 15:33:44 CST 2024, time=2024-11-18, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2251509, encodeId=d8e22251509fb, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肺癌 经验分享：21 Jan 2025 (12:22:40) Article accepted for publication. 10 Jan 2025 (12:23:49) Review of Reviewer 1 finalized. (11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript. (11:03:16) Corresponding Author Peng Xiuhua posted new comments. (10:27:56) Corresponding Author Peng Xiuhua posted new comments. 23 Dec 2024 (18:05:16) Review of Reviewer 2 finalized. (18:01:29) Reviewer 2 posted new comments. 20 Dec 2024 (09:46:36) Corresponding Author Peng Xiuhua posted new comments. 10 Dec 2024 (08:40:46) Interactive review forum activated. 24 Nov 2024 (13:36:44) Corresponding Author Peng Xiuhua submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47509306346, createdName=ms7000000739039843, createdTime=Tue Feb 11 20:39:18 CST 2025, time=2025-02-11, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251508, encodeId=fb5522515082b, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肺癌 经验分享：21 Jan 2025 (12:22:40) Article accepted for publication. 10 Jan 2025 (12:23:49) Review of Reviewer 1 finalized. (11:10:12) Corresponding Author Peng Xiuhua resubmitted the manuscript. (11:03:16) Corresponding Author Peng Xiuhua posted new comments. (10:27:56) Corresponding Author Peng Xiuhua posted new comments. 23 Dec 2024 (18:05:16) Review of Reviewer 2 finalized. (18:01:29) Reviewer 2 posted new comments. 20 Dec 2024 (09:46:36) Corresponding Author Peng Xiuhua posted new comments. 10 Dec 2024 (08:40:46) Interactive review forum activated. 24 Nov 2024 (13:36:44) Corresponding Author Peng Xiuhua submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47509306346, createdName=ms7000000739039843, createdTime=Tue Feb 11 20:37:39 CST 2025, time=2025-02-11, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2246390, encodeId=2185224639036, content=我提交一篇文章已经1个月了，也不知道怎么查看现在的状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05072053931, createdName=huagangyan2018, createdTime=Fri Jan 03 16:21:34 CST 2025, time=2025-01-03, status=1, ipAttribution=广西)]

2025-01-03 huagangyan2018 来自广西

我提交一篇文章已经1个月了，也不知道怎么查看现在的状态

0 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务